Close

Health

The Health Section develops policy positions that promote biomedical innovation and represent the best interests of BIO member companies with a direct interest in human health. Among the priority issues the Health Section focuses on are matters affecting the healthcare-related regulatory and reimbursement climate, pandemic and biodefense preparedness, publicly-funded scientific research, and personalized medicine. The Health Section is managed by a Section governing body and recommends members to sit on BIO's Board of Directors.
Staff Contact: Kay Holcombe

Ron Cohen, MD, Chair
Acorda Therapeutics, Inc

Paul J. Hastings, Vice Chair
OncoMed Pharmaceuticals, Inc

Rachel K. King, Immediate Past Chair
GlycoMimetics, Inc

Kristine Peterson, Secretary
Valeritas, Inc

Daniel Apel
Bayer Healthcare LLC

Stuart A. Arbuckle
Vertex Pharmaceuticals Incorporated

Alex M. Azar II
Eli Lilly and Company

Jean-Jacques Bienaimé
BioMarin Pharmaceutical, Inc

Ian T. Clark
Roche

Stanley T. Crooke, MD, PhD
Isis Pharmaceuticals, Inc

John F. Crowley, JD, MBA
Amicus Therapeutics, Inc

Douglas A. Doerfler
MaxCyte, Inc

Deborah Dunsire, MD
FORUM Pharmaceuticals Inc

Paul R. Eisenberg, MD, MPH
Amgen Inc.

Mark Enyedy
Shire

William Fitzsimmons, PharmD, MS
Astellas Pharma US

Julie L. Gerberding, MD, MPH
Merck & Co, Inc

Geno Germano
Pfizer Inc

John Glasspool
Baxalta

Glenn Gormley, MD, PhD
Daiichi Sankyo Pharma Development

Maxine Gowen, PhD
Trevena, Inc.

Peter S. Greenleaf
Sucampo Pharmaceuticals, Inc

David Hallal
Alexion Pharmaceuticals, Inc

Russell H. Herndon
Hydra Biosciences, Inc

Steven H. Holtzman
Biogen

Hervé Hoppenot
Incyte Corporation

Paul Hudson
AstraZeneca, Plc

Daniel M. Junius
ImmunoGen, Inc

Perry Karsen
Celgene Corporation

Scott Koenig, MD, PhD
MacroGenics, Inc

Nick Leschly
bluebird bio

Sabine Luik, MD, MPH
Boehringer Ingelheim Pharmaceuticals, Inc.

John Maraganore, PhD
Alnylam Pharmaceuticals, Inc

Thomas P. Mathers
CoLucid Pharmaceuticals, Inc

David P. Meeker, MD
Genzyme Corporation, A Sanofi Company

Steven J. Mento, PhD
Conatus Pharmaceuticals, Inc

John F. Milligan, PhD
Gilead Sciences, Inc

Michael Narachi
Orexigen Therapeutics, Inc

John A. Orwin
Relypsa, Inc

Paris Panayiotopoulos
EMD Serono, Inc

Adelene Q. Perkins
Infinity Pharmaceuticals, Inc.

Richard Pops
Alkermes, Inc.

Robert Repella
CSL Behring

Howard W. Robin
Nektar Therapeutics, Inc

Timothy C. Rodell, M.D.
GlobeImmune, Inc.

Raymond Sacchetti
Bristol-Myers Squibb

David Schenkein, MD
Agios Pharmaceuticals, Inc

Michael Severino, MD
AbbVie Inc.

Christi L. Shaw
Novartis Pharmaceuticals Corporation

Jay P. Siegel, MD
Johnson & Johnson

Mark Skaletsky
Fenway Pharmaceuticals, Inc

Moncef Slaoui, PhD
GSK

David M. Stack
Pacira Pharmaceuticals, Inc.

Henri A. Termeer
AVEO Pharmaceuticals, Inc.

Mark Timney
Purdue Pharma LP

Gil Van Bokkelen, PhD
Athersys, Inc

Harold E. Van Wart, PhD
CymaBay Therapeutics

H. Thomas Watkins, Immediate Past Chair
Chair Emeritus, BIO

Allen Waxman
Eisai, Inc.

Edward Williams
Novo Nordisk

Rick E. Winningham
Theravance Biopharma US, Inc.

Jeffrey Wren
UCB, Inc